Ind-Swift Power Play: NCLT Seals Mega Pharma Merger, Ushering New Era of Innovation!

In a landmark decision today, the National Company Law Tribunal (NCLT), Chandigarh Bench, has approved the much-anticipated Scheme of Arrangement for the amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited. The judgment, pronounced on July 17, 2025, follows the initial intimation made by the companies on May 29, 2025, and marks a pivotal consolidation move in India’s pharmaceutical sector.

 

The amalgamation, effective retroactively from March 31, 2024, is set to create synergistic benefits for both entities, enhancing operational efficiency and market reach, while also streamlining resources between the two organizations for the benefit of shareholders and creditors.

 

Key Highlights:

 

NCLT Approval: The NCLT, Chandigarh Bench, formally sanctioned the merger today after detailed hearings, bringing the companies a step closer to unified operations.

 

Appointed Date Set: The amalgamation scheme will take effect from March 31, 2024, as the appointed date for all operational, legal, and accounting purposes.

 

Strategic Consolidation: This step aims to maximize value for stakeholders by combining the strengths and resources of both Ind-Swift Limited and Ind-Swift Laboratories Limited.

 

Regulatory Compliance: The approval comes under Sections 230 and 232 of the Companies Act, 2013, ensuring statutory and regulatory transparency.

 

This development signals a new growth trajectory for the merged entity, positioning it for a stronger competitive edge in the pharmaceutical space.

 

Source: Regulatory announcement to stock exchanges on July 17, 2025 and prior company filings.